Montreux Closes $250M Life Sciences Fund
Menlo Park-based Montreux Equity Partners said Thursday that the venture capital firm has closed $250M Montreux Equity Partners IV, L.P. The firm said the fund, which is focused on therapeutic-oriented life sciences companies, received support from existing investors and new institutional investors. The fund target was $200M. Montreux's most notable exits are Orexigen (IPO), Cerexa (Forest Laboratories), Novacardia (Merck) and Peninsula Pharmaceuticals (Johnson & Johnson). Montreux said that Lazard Freres & Co., L.L.C., acted as placement agent for for the firm.
posted on Thursday, January 3, 2008
Related companies:
Montreux Equity Partners
Related stories:
> 5AM Ventures Closes $200M Life Sciences Fund
> Longitude Capital Closes $325M Fund
> Vivo Ventures Closes $275M Life Science Venture Fund
> Founders Fund Closes $250M Fund
> Frazier Healthcare Partners Announces $262M Life Sciences Fund
silicontap.com Home